Key facts
- It has raised $62.7M; the latest was Early Stage VC ($44.0M) in Aug 2025.
- Notable investors include Tech Incubator Program for Startup, KB Investment, Hana Ventures, Schmidt (South Korea), T.S. Investment — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for NEX-I
- ·The full record, as it builds
Funding rounds
No funding rounds for NEX-I are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NEX-I
Developer of next-generation Immunotherapeutics designed to induce cancer cells to become refractory to the current treatment. The company's platform designs assessment tools for the target efficacy of cancer immunotherapy and is looking to change the current regime of the standard of care in anti-cancer therapies to provide new clinical values, enabling healthcare providers to improve the quality of patients' lives.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2021
- Employees
- 36
- Website
- nex-i.co.kr/
- Ownership
- Privately Held (backing)
NEX-I doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NEX-I shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NEX-I in its N-PORT filings yet. We sweep new filings monthly.